Christophe Bergeron

Incidence of Sarcoma Histotypes and Molecular Subtypes in a Prospective Epidemiological Study with Central Pathology Review and Molecular Testing

Françoise Ducimetière, A. Lurkin, Dominique Ranchère‐Vince et al. · PLoS ONE · 2011 · 546 citations · Full text

Medicine, Oncology, Pathology +17

Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomised, phase 3 trial

Gianni Bisogno, Gian Luca De Salvo, Christophe Bergeron et al. · The Lancet Oncology · 2019 · 240 citations · Full text

Medicine, Oncology, Pharmacology +12

Frequent <i>hSNF5/INI1</i> Germline Mutations in Patients with Rhabdoid Tumor

Franck Bourdeaut, Delphine Lequin, Laurence Brugières et al. · Clinical Cancer Research · 2011 · 222 citations · Full text

Life Sciences, Genetics, Molecular Genetics +14

Omission of doxorubicin from the treatment of stage II–III, intermediate-risk Wilms' tumour (SIOP WT 2001): an open-label, non-inferiority, randomised controlled trial

Kathy Pritchard‐Jones, Christophe Bergeron, Beatriz de Camargo et al. · The Lancet · 2015 · 206 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Randomized Comparison of Intensified Six-Drug Versus Standard Three-Drug Chemotherapy for High-Risk Nonmetastatic Rhabdomyosarcoma and Other Chemotherapy-Sensitive Childhood Soft Tissue Sarcomas: Long-Term Results From the International Society of Pediatric Oncology MMT95 Study

Odile Oberlin, Annie Rey, Hélène Martelli et al. · Journal of Clinical Oncology · 2012 · 189 citations · Full text

Medicine, Oncology, Pediatrics +17